An observational study in Coronary Artery Disease and Percutaneous Coronary Intervention, sponsored by University of Freiburg. Recruiting at 1 site in Switzerland. Open to participants aged 17 Years to 120 Years. Per ClinicalTrials.gov, last updated 2021-10-22.
Sponsored by University of Freiburg · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Coronary Artery Disease with a site in Switzerland — 31 open to participants now, 41 under way, 4 of them phase 3. Coronary Artery Disease · Switzerland.
Among the 177 studies in Coronary Artery Disease with a site in Switzerland, this one is the 14th largest by planned enrollment of the 52 observational ones that give a count, is one of 8 that started in 2015, is one of 52 observational ones, reaches primary completion later than 0 of the 40 other live ones, and was the 129th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →31 of the 177 studies in Coronary Artery Disease with a site in Switzerland are open now. Recruiting first, the newest first:
B. Braun Melsungen AG · Sites in Switzerland, Germany
Ages 18+
IGLESIAS Juan Fernando · Sites in Switzerland
Ages 18+
Translumina GmbH · Sites in Switzerland
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
University Hospital, Geneva · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 17 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 17 · Phase 4 25
First in 2002; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 296 across the 125 interventional studies, 992 across the 52 observational. Of the 114 that completed or were terminated, 25 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 177 have an industry lead sponsor. The 10 most frequent:
University of Freiburg is the lead sponsor of 27 studies on the registry; 5 are open to participants now.
University of Freiburg has 5 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Coronary Artery Disease with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04988685Luzerner KantonsspitalSIROOP Registry - a Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated with SIROlimus or Paclitaxel Eluting Balloon Catheters | 2026-12-31 |
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT05027984Centro per la Lotta Contro l'Infarto - Fondazione OnlusInterventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS | 2027-01-31 |
| NCT06706323Roland von KänelDepressive Symptoms After Cardiac Surgery | 2027-04-01 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 177 studies in Coronary Artery Disease with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The registry aims to follow clinically all consecutive patients treated by percutaneous coronary interventions at hospital \& university Fribourg.
All comers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient-oriented composite endpoints (POCE)
Academic Research Consortium definition
Time frame: 2 years
Major Bleeding
Bleeding Academic Research Consortium definition
Time frame: 2 years
Patient-oriented composite endpoints (POCE)
Academic Research Consortium definition
Time frame: 5 years
Major Bleeding
Bleeding Academic Research Consortium definition
Time frame: 5 years
Patient-oriented composite endpoints (POCE)
Academic Research Consortium definition
Time frame: 10 years
Major Bleeding
Bleeding Academic Research Consortium definition
Time frame: 10 years
all-cause death
Academic Research Consortium definition
Time frame: 2 years
any revascularization
Academic Research Consortium definition
Time frame: 2 years
any myocardial infarction
Academic Research Consortium definition
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2015 to primary completion in Sep 2017, 28 months.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's 28 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Freiburg